This new position paper proposes 5 pre-defined business priorities to help pharma affiliates adjust to the changes of HCPs expectations, so that to keep them engaged in the post-Covid-19 era.
News
Developing a strategy for rare diseases in France requires a clear understanding of the care ecosystem, key...
The French Voluntary Trade Organization (VTO) market is consolidating, making VTOs increasingly important partners for pharma companies...
« High-performance Market Access Brand Plans require method, rigor and pragmatism » Our new publication on how to build...